Skip to main content
Premium Trial:

Request an Annual Quote

PROOF, Adiga Collaborate on Biomarkers for Allergy Vaccines

NEW YORK (GenomeWeb News) – Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF) and Adiga Life Sciences announced today a collaboration to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.

Knowledge gained from the project is expected to lead to a better understanding of how such vaccines work, which will then be used to guide development of molecular tests for diagnosing and managing allergic rhinitis, PROOF said.

Adiga is currently collaborating with researchers from AllerGen NCE — a network of allergy and immune disease experts in Canada whose goal is to discover the causes of allergies and immune-related diseases — in a clinical trial with patients being treated with an investigational peptide allergy vaccine.

Under the partnership announced today, PROOF and Adiga will use patient samples from the trial for a biomarker discovery and validation program that has been established and refined by PROOF.

The partners aim to identify protein and genetic biomarkers that respond to vaccine treatment. Bruce McManus, director of the PROOF Centre, said in a statement that the biomarkers "will support the development of products for quicker relief from allergy symptoms as well as for more effective clinical management of those suffering from allergic rhinitis."

Financial and other terms of the deal were not disclosed.

PROOF, is a not-for-profit organization based in Vancouver, British Columbia that develops biomarker-based tests for patients with heart, lung, and kidney diseases. Based in Hamilton, Ontario, Adiga is a joint venture between McMaster University and UK-based biopharmaceutical firm Circassia and identifies and commercializes promising early-stage Canadian medical technologies.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.